Suzanne Harris is a veteran patient advocate and the Senior Vice President of Marketing & Communications at SubjectWell, where she spearheads initiatives to modernize the intersection of clinical research and patient engagement. With a deep focus on patient-centric solutions, she has become a
The global biotechnology sector is currently navigating a pivotal transition as companies move beyond traditional dopamine-replacement therapies to explore more sophisticated neurological pathways. This shift is most visible in the recent strategic expansion of Vima Therapeutics, a Cambridge-based
The intersection of speculative finance and molecular biology creates a high-stakes environment where a single laboratory result can instantly wipe out or multiply a company’s enterprise value by an order of magnitude. Determining the financial worth of an early-stage life sciences company remains o
The silent observations of a caregiver watching a loved one's fingers twitch with newfound intent often stand in stark contrast to the rigid, binary data captured by antiquated medical surveys. While these subtle flickers of regained movement or the first signs of motor decay represent the
The recent acquisition of Day One Biopharmaceuticals by Servier for approximately $2.5 billion marks a definitive turning point in the competitive landscape of rare oncology and precision medicine. By securing all outstanding shares of the South San Francisco-based biotech firm at $21.50 per share,
The medical community is closely watching the evolution of Atavistik Bio, a company leveraging a unique metabolic signaling platform to tackle diseases that have long lacked targeted solutions. Led by research originating from the University of Utah, the firm is currently transitioning into a
